Due to the versatile application and based on pre-clinical evidence, clinical trials have been launched (Table S7) combining vorinostat with pembrolizumab (NCT02619253) and enantiostat with aldesleukin (interleukin 2; ClinicalTrials.gov Identifier: NCT01038778 [69]) for the treatment of RCC. Here, IL2 is linked to renal cell carcinoma.